Remdesivir OK'd in India at $39-52 per dose

Jun. 21, 2020 4:56 PM ETGilead Sciences, Inc. (GILD)GILDBy: Douglas W. House, SA News Editor105 Comments
  • India's Controller General has approved generic versions of Gilead Sciences' (NASDAQ:GILD) remdesivir for the treatment of COVID-19.
  • Two domestic drugmakers, Hyderabad-based Hetero and Mumbai-based Cipla, plan to launch their offerings within a week at Rs 5,000-6,000 ($65-78) and Rs 3,000-4,000 ($39-52), respectively.
  • According to current Indian government guidelines, a COVID-19 patient may need five-to-six doses, implying a total treatment cost of the antiviral as low as $195.
  • Gilead has yet to announce the price in the U.S. but it's safe to say it will be substantially higher. Drug cost watchdog ICER issued a report last month that the medicine would be cost-effective at $4,500 per course of treatment.
  • Update: On Monday, June 22, Cipla announced the market launch of its product, branded as Cipremi.

Recommended For You

Comments (105)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.